期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/ijms23042288
关键词
breast cancer; breast cancer treatment; HER2; targeted therapy; emerging therapies
This article discusses the incidence and classification of breast cancer in the United States, and explores the main treatment methods, including surgery, radiation therapy, chemotherapy, endocrine therapy, and targeted therapy. It also highlights the research focus on triple-negative breast cancer treatment.
In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据